253666 Neurotechnology, pharmaceutics, insurance coverage, and pain care: Policy toward alignment

Monday, October 31, 2011: 2:50 PM

James Giordano, PhD , Center for Neurotechnology Studies, Potomac Institute for Policy Studies, Arlington, VA
     
Advances in biomedical science (eg- neurotechnology, pharmaceutics, etc) have profound potential to improve diagnosis and treatment of chronic pain, yet translational efforts may be stultified by misalignment of healthcare coverage. This presentation addresses this schism and posits means to resolve such dissonance through policy development and articulation.

Learning Areas:
Provision of health care to the public
Public health or related laws, regulations, standards, or guidelines
Public health or related public policy

Learning Objectives:
Describe current domains of biomedical technology that have potential for translation into pain care, and how policy might be employed to facilitate and maximize such translation.

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am director of a national Center (for Neurotechnology Studies) that (1) addresses, analyzes, and forecasts trends and dynamics in several aspects of public health (eg- pain care, neurology, psychiatry), and (2) is directly involved with informing and developing federal healthcare policy.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

See more of: Health Industries, Medicare, and National Health Reform
See more of: APHA-Conference of Emeritus Members